Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer

Trial Profile

An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Dec 2018

At a glance

  • Drugs Cabozantinib (Primary)
  • Indications Adenocarcinoma; Thyroid cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms EXAM
  • Sponsors Exelixis
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 22 Sep 2017 Results published in the Annals of Oncology
    • 01 Aug 2017 Results of factors impacting QTc interval data from this study published in the Cancer Chemotherapy and Pharmacology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top